相关实验视频

Updated: Jun 22, 2025

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

从癌细胞中提取的外体细胞可以缓解小鼠的炎症性肠病

Shuyi Zhang¹, Guangyao Li¹, Kewen Qian²

¹Department of Biophysics, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.

Journal of drug targeting

|July 3, 2024

概括

瘤细胞衍生外体 (TDE) 显示出治疗炎症性肠病 (IBD) 的前景. 这些外体细胞在小鼠模型中减少了炎症并改善了结肠健康,这表明了基于外体细胞的免疫治疗的潜力.

科学领域:

免疫学免疫学免疫学
细胞生物学细胞生物学
纳米医学是一种纳米医学.

背景情况:

外体,特别是瘤细胞衍生外体 (TDE),具有固有的免疫调节特性.
TDEs可以与免疫细胞相互作用并修改瘤微环境,抑制免疫反应.
它们的定位能力和低毒性使它们对治疗应用具有吸引力.

研究的目的:

研究TDE在治疗炎症性疾病,特别是炎症性肠病 (IBD) 的潜力.
在DSS诱导的IBD小鼠模型中,评估来自小鼠结肠癌细胞 (CT26 exo) 的外体的治疗疗效和潜在机制.

主要方法:

用超离心法分离CT26外体并进行了表征.
在分离的外体体上进行了蛋白质组分析.
在硫酸 (DSS) 诱导的IBD小鼠模型中评估了治疗潜力,评估了疾病活性指数 (DAI) 和结肠组织学.

主要成果:

与对照组相比,CT26外体治疗在IBD小鼠中显著降低了DAI和结肠缩短.
组织学分析显示,在接受治疗的小鼠的结肠中,炎症透率降低,杯状细胞增加.
机理学研究表明,CT26外体抑制了树突细胞 (DC) 的促炎性细胞因子分泌,并抑制了Th17细胞的分化.

结论:

瘤细胞衍生外体 (CT26外体) 显示出炎症性肠病 (IBD) 的显著治疗潜力.
免疫调节作用包括抑制DC促炎性细胞因子释放和Th17细胞分化.
TDEs代表了一种有希望的,安全的,和新的治疗策略,用于炎症性疾病.

关键词:

IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 免疫治疗是一种免疫疗法.外基因组是外基因组的组成部分.炎症性肠病是一种炎症性肠病.瘤衍生的外体细胞.

更多相关视频

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

相关概念视频

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...